drugset / Trial / NCT00267085
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
Timeline
- Start
- 2005-12
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Synthetic Tumor-Specific Breakpoint Peptide Vaccine | Vaccine | — | Subcutaneous |
| Background | Imatinib | Small molecule | — | Subcutaneous |